Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse Other stock markets 02:30:02 07/02/2026 am IST			5-day change	1st Jan Change
10.92 ^USD	+3.61%		-3.70%	-11.65%

16/01	Powell Investigation Upends Final Stretch of Fed Chair Contest	DJ
16/01	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Sector Update: Health Care Stocks Softer Late Afternoon

Published on 01/16/2026 at 02:10 am IST

MT Newswires

Latest news about Emergent BioSolutions Inc.

16/01	Powell Investigation Upends Final Stretch of Fed Chair Contest	DJ
16/01	Sector Update: Health Care Stocks Softer Late Afternoon	MT
16/01	Top Midday Decliners	MT
16/01	Emergent announces resolution of New York attorney general investigation	RE
16/01	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
15/01	Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination	RE
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update	DJ
15/01	Emergent BioSolutions' Former CEO Sued for Insider Trading by New York Attorney General	MT
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading	DJ
15/01	Emergent BioSolutions Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
14/01	Emergent Biosolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to Be Packaged in A New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness	CI
14/01	Emergent BioSolutions Says US FDA Approves sNDA for New Packaging for Narcan Nasal Spray	MT
14/01	Emergent BioSolutions receives U.S. FDA approval on supplemental new drug application for Narcan nasal spray to be packaged in a new carrying case, making life-saving naloxone more accessible for everyday preparedness	RE
13/01	Emergent BioSolutions, Inc. Announces Voluntary Prepayment of $100 Million Under its Outstanding Term Loan Facility	CI
12/01	Emergent BioSolutions announces $100 million paydown of term loan principal, a significant step achieved toward its multi-year transformation	RE
09/01	Emergent BioSolutions Gets $21.5 Million Anthrax Vaccination Order From Pentagon	DJ
09/01	Emergent BioSolutions Receives $21.5 Million Delivery Order for BioThrax	MT
09/01	Emergent BioSolutions receives $21.5 million order from U.S. Department of War to supply Biothrax in 2026	RE
09/01	Emergent BioSolutions Receives Delivery Order Up to $21.5 Million to Supply BioThrax®? ( Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026	CI
08/01	Emergent BioSolutions, Panther Collaborate to Advance Mpox Research in Africa	MT
08/01	Emergent Biosolutions and Panther Announce Agreement to Support the Continuation of the Africa Cdc-Led Mpox Study in Africa	CI
08/01	Emergent BioSolutions and Panther announce agreement to support the continuation of the Africa CDC-led Mpox study in Africa	RE
12/12	Emergent Biosolutions Receives U.S. FDA Approval for Drug Product Manufacturing of Raxibacumab At Its Winnipeg, Canada Site	CI
12/12	Emergent BioSolutions Says FDA Approved SBLA to Add Winnipeg Site for Raxibacumab Work	MT
18/11	Emergent BioSolutions marks 10-year anniversary of the U.S. FDA approval of Narcan nasal spray and reinforces its commitment to increasing naloxone access	RE

Chart Emergent BioSolutions Inc.

Duration

Period

EBS: Dynamic Chart

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Employees

900

Sector

Pharmaceuticals

Calendar

10/03 - Q4 2025 Earnings Release (Projected)

More about the company